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Sirs,
Barshop [1] recently described some key variables in the
clinical assessment of nephropathic cystinosis. We wish to
add to that list. Cystinosis is an autosomal recessive disease
of altered intracellular organelle cystine transport that leads
to kidney failure and other critical organ dysfunction when
untreated. The current approved treatment requires frequent
aminothiol (Cystagon®) administration. The efficacy of
Cystagon® treatment is reflected in the leukocyte cystine
level. It is essential to measure leukocyte cystine levels
accurately, both to diagnose the disease and to monitor
treatment, as well as for clinical trials testing new cystinosis
therapies. In a recent phase 3 study of a novel, delayed-
release form of cysteamine sponsored by Raptor Pharma-
ceutical, patients were enrolled worldwide, using a single
contract laboratory, but at two sites for the leukocyte cystine
level determinations. Each clinical center received training
to use the same method of leukocyte preparation prior to off-
site clinical assays. Unfortunately, an unexpected problem
quickly arose. This letter describes the problem, how it was
corrected, and warns the medical community of a potential
problem in the care of cystinosis patients.
Blood was anticoagulated with heparin and leukocytes
prepared promptly after the blood was obtained. The leuko-
cytes were lysed and immediately acid-precipitated with
sulfosalicylic acid. The acid pH stabilized the cystine in
the supernatant and the protein pellet was dissolved in base.
Both the cystine and protein were stable until assayed under
these conditions. Cystine concentrations were measured using
a highly accurate mass spectrophotometric method.
Although the usual method of reporting the level of a
substance is by its concentration, the volume of the leukocytes
is much too small to measure and hence, relying on precedent
set in 1967 by Schneider et al. [2], cystine levels in cell
preparations have been arbitrarily reported as nmol half-
cystine/mg total protein in the cell lysate. Based on the same
precedent, the Lowry assay, with bovine serum albumin as the
standard, has been used as the default quantitation method for
the total protein content of leukocyte lysate.
To qualify for the delayed-release cysteamine study,
patients had to have leukocyte cystine levels of less than
1 nmol half-cystine/mg total protein. As described, total
protein was determined by the Lowry assay. Although all
patients initially met the requirement, many were subse-
quently found to have cystine levels greater than 1.0 at the
time they entered the study. This discrepancy was found to
correspond to a change in the leukocyte lysate total protein
assay used by the contract clinical laboratory that used the
BCA protein assay rather than the Lowry assay. Comparison
of BCA and Lowry total protein assay values, using a
bovine serum albumin standard, from 106 clinical samples
from patients with cystinosis, revealed a significant and
consistent difference in values from identical samples. The
mean and standard deviation of the ratio between BCA and
Lowry results over all samples was 0.65±0.07.
Discovery of the discrepancy in total protein values
allowed values to be normalized and the study to proceed.
We suspect that the discrepancies observed are based on
variable assay sensitivity to different protein types, as has
been noted by others [3]. Obviously, the choice of protein
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assay is completely arbitrary. This is just one of the many
things that can influence the results of leukocyte cystine
assays. Laboratories that assay leukocyte cystine must estab-
lish an exact system of preparing cells and performing both
the cystine and protein assays, and then establish their own
standard values. Clinicians should understand which protein
assay is being used in interpretation of the leukocyte cystine
levels at diagnosis and in making therapeutic decisions.
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